DUBLIN, April 17, 2014 /PRNewswire/ --
Dublin - Research and Markets (http://www.researchandmarkets.com/research/kdxh24/global) has announced the addition of the "Global Radiopharmaceutical Market Report" report to their offering.
(Logo: http://photos.prnewswire.com/prnh/20130307/600769 )
The analysts forecast the Global Radio Pharmaceutical market to grow at a CAGR of 18.39 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing aging population. The Global Radio Pharmaceutical market has also been witnessing the increasing demand for radiopharmaceuticals. However, the short half-life could pose a challenge to the growth of this market.
The report, the Global Radio Pharmaceutical Market 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Radio Pharmaceutical market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
The key vendors dominating this market space are Cardinal Health Inc., Covidien plc, Lantheus Medical Imaging Inc., and IBA Molecular Inc.
Other vendors mentioned in the report are Advanced Medical Isotope Corp., Advanced Accelerator Applications SA, Algeta ASA, Bio-Nucleonics Inc., GE Healthcare Ltd., Monrol Nuclear Products Inc., Molecular Insight Pharmaceuticals Inc., Nordion Inc., Novelos Therapeutics Inc., NTP Radioisotopes (Pty) Ltd., Positron Corp., and Siemens Healthcare.
As a result of the rise in the incidences of cardiovascular, oncological, and neurological disorders among the population, there has been an increase in procedural volumes for PET, SPECT, SPECT-CT, PET-MRI, and SPECT-MRI procedures for imaging and diagnosis. Imaging without utilization of radiopharmaceuticals has become indispensable owing to their ability to enable diagnosis of various disease processes much earlier than other diagnostic test procedures.
For instance, the increasing number of oncology and cardiology procedures is expected to drive the demand for radiopharmaceuticals such as fluorodeoxyglucose used for PET scans. Thus, increasing demand for radiopharmaceuticals is expected to fuel the growth in this market.
According to the report, one of the main drivers in this market is the increasing aging population globally and the associated increase in incidences of cardiovascular diseases, neurological disorders, gastrointestinal diseases and oncological disorders among the aged population. The rise in demand for diagnostic screening of elderly patients has enhanced the need for radiopharmaceuticals.
Further, the report states that one of the major challenges faced by the market is the high cost of devices using radioisotopes. Various smaller end-users do not have the required budget to buy such costly devices and settle for low-cost alternative devices.
Key Topics Covered:
01. Executive Summary
02. Scope of the Report
03. Market Research Methodology
04. List of Abbreviations
06. Market Landscape
07. Global Radiopharmaceuticals Market Segmentation by Application
08. Geographical Segmentation
09. Key Leading Countries
10. Buying Criteria
11. Market Growth Drivers
12. Drivers and their Impact
13. Market Challenges
14. Impact of Drivers and Challenges
15. Market Trends
16. Trends and their Impact
17. Vendor Landscape
18. Key Vendor Analysis
19. Other Reports in this Series
- Advanced Accelerator Applications SA
- Advanced Medical Isotope Corp.
- Algeta ASA
- Bio-Nucleonics Inc.
- Cardinal Health Inc.
- Covidien plc
- GE Healthcare Ltd.
- IBA Molecular Inc.
- Lantheus Medical Imaging Inc.
- Molecular Insight Pharmaceuticals Inc.
- Monrol Nuclear Products Inc.
- NTP Radioisotopes (Pty) Ltd.
- Nordion Inc.
- Novelos Therapeutics Inc.
- Positron Corp.
- Siemens Healthcare.
For more information visit http://www.researchandmarkets.com/research/kdxh24/global
Media Contact: Laura Wood , +353-1-481-1716, [email protected]
SOURCE Research and Markets